Bristol-Myers Squibb Co (BMY) Position Reduced by Retirement Systems of Alabama

Retirement Systems of Alabama lowered its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 0.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,250,617 shares of the biopharmaceutical company’s stock after selling 3,149 shares during the period. Retirement Systems of Alabama’s holdings in Bristol-Myers Squibb were worth $79,714,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Blue Chip Partners Inc. grew its stake in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in Bristol-Myers Squibb by 0.4% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 15 shares in the last quarter. Chilton Investment Co. LLC grew its stake in Bristol-Myers Squibb by 0.5% during the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 26 shares in the last quarter. Keel Point LLC grew its stake in Bristol-Myers Squibb by 0.6% during the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 39 shares in the last quarter. Finally, Hudock Capital Group LLC grew its stake in Bristol-Myers Squibb by 0.4% during the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 49 shares in the last quarter. 69.67% of the stock is owned by institutional investors.

In related news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II purchased 4,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.

Shares of Bristol-Myers Squibb Co (BMY) opened at $62.81 on Friday. The firm has a market cap of $102,800.00, a P/E ratio of 24.73, a PEG ratio of 2.22 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Co has a 1-year low of $46.01 and a 1-year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. research analysts predict that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.55%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 62.99%.

A number of research firms have commented on BMY. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target for the company. in a research note on Thursday, September 28th. Jefferies Group reissued a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Cowen reissued a “hold” rating and issued a $65.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $65.05.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.com-unik.info/2018/01/13/bristol-myers-squibb-co-bmy-position-reduced-by-retirement-systems-of-alabama.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit